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Clinical studies have demonstrated that inhaled nitricoxide (NO), even in low doses, can reduce elevatedpulmonary artery pressure and pulmonary vascular re-sistance in infants and children with severe pulmonary
hypertension after cardiac operations without relevant negative
side effects on systemic circulation.1 However, several studies
have observed a rebound effect after abrupt discontinuation of NO.
This rebound effect leads to pulmonary vasoconstriction and de-
terioration of oxygenation.2 On the other hand, intravenous
epoprostenol (prostacyclin) is considered a potential pulmonary
vasodilator for severe pulmonary hypertension. A synergistic ef-
fect of intravenous epoprostenol and inhaled NO has been reported
after cardiopulmonary bypass.3
Clinical Summaries
Between March 2000 and February 2001, a total of 3 patients
needed inhaled NO therapy after the Fontan procedure. In 2 of
these 3 cases, discontinuation of inhaled NO resulted in worsening
of the cardiorespiratory state, so combined therapy with inhaled
NO and intravenous epoprostenol was applied.
PATIENT 1. The patient was a boy aged 2 years, 11 months with
the diagnosis of pulmonary atresia with intact ventricular septum
and hypoplastic right ventricle. He underwent a modified Fontan
procedure (extracardiac total cavopulmonary connection with an
18-mm polytetrafluoroethylene graft). The patient’s hemodynamic
parameters were stable with superior and inferior vena caval
pressure (measured as central venous pressure [CVP]) of 11 mm
Hg and common atrial pressure (measured as left atrial pressure
[LAP]) of 4 mm Hg. Six hours after the operation the LAP
decreased to 3 mm Hg and the CVP increased 15 mm Hg, so that
the transpulmonary pressure gradient (CVP-LAP) was increased to
12 mm Hg. Inhaled NO therapy at 2.5 ppm was then started, and
the patient’s hemodynamic status improved significantly (CVP
decreased to 11 mm Hg and CVP-LAP to 7 mm Hg). After 12
hours of stable hemodynamic status, we started weaning the pa-
tient from inhaled NO by decreasing NO concentration by 1.0 ppm
every hour and finally discontinuing inhaled NO. Fifteen minutes
after discontinuation, the patient’s systemic arterial pressure was
unchanged; however, CVP-LAP increased from 6 to 10 mm Hg
(CVP increased from 12 to 14 mm Hg and LAP decreased from 6
to 4 mm Hg). The patient’s PO2 significantly decreased from 94.8
mm Hg to 64.9 mm Hg. Inhaled NO at 2.5 ppm was then restarted,
and the CVP-LAP returned to 6 mm Hg and the PO2 increased to
90.1 mm Hg. Intravenous epoprostenol at an initial dose of 2
ng/kg/min was started, increasing incrementally in steps of 2
ng/kg/h to a dose of 8 ng/kg/min. During therapy with intravenous
epoprostenol at 8 ng/kg/min, inhaled NO was discontinued. This
time systemic arterial pressure, CVP, LAP, and CVP-LAP were
unchanged, and PO2 decreased slightly from 89.6 mm Hg to 76.6
mm Hg (arterial oxygen saturation from 97.4% to 96.2%; Figure
1). The inhaled NO was successfully discontinued, and 2 hours
later the patient was extubated. The intravenous epoprostenol was
decreased by 2 ng/kg every 12 hours and discontinued completely
85 hours after extubation.
PATIENT 2. The patient was a 4-year-old girl with a diagnosis of
univentricular heart (right ventricular type), pulmonary stenosis,
and double-outlet right ventricle. She underwent a fenestrated
Fontan procedure (extracardiac total cavopulmonary connection
with 18-mm polytetrafluoroethylene graft with 4-mm polytetra-
fluoroethylene graft fenestration). After bypass the patient re-
mained in hemodynamically stable condition with a CVP of 13
mm Hg and an LAP of 5 mm Hg. Two hours after the operation the
patient had a junctional tachycardia (heart rate  170 beats/min),
her LAP decreased to 3 mm Hg, her CVP increased to 17 mm Hg,
and her CVP-LAP increased to 14 mm Hg. Inhaled NO therapy
was then started at 2.5 ppm, and the patient’s hemodynamic status
improved (CVP decreased to 12 mm Hg and CVP-LAP decreased
from 14 to 8 mm Hg). On the sixth postoperative day, cineangiog-
raphy showed total occlusion of the inferior vena cava and total
cavopulmonary connection conduit because of thrombosis.
Thrombectomy of the inferior vena cava and total cavopulmonary
connection conduit and revision of fenestration (5-mm polytetra-
fluoroethylene graft) were performed. The patient’s hemodynamic
condition restabilized, with a CVP of 15 mm Hg and an LAP of 7
mm Hg. In the unit inhaled NO was given at the same dose before
surgery. After 12 hours of stable hemodynamic status, we started
weaning the patient from inhaled NO by decreasing the NO
concentration by 1.0 ppm every hour and finally discontinuing
inhaled NO. Fifteen minutes after discontinuation, systemic arte-
rial pressure was unchanged; however, CVP-LAP had increased
from 7 to 10 mm Hg (CVP from 15 to 16 mm Hg and LAP from
8 mm Hg to 6 mm Hg). Her PO2 significantly decreased from 78.1
mm Hg to 57.7 mm Hg. At that point inhaled NO was restarted at
2.5 ppm, and the CVP-LAP decreased to 6 mm Hg and the PO2
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increased to 70.7 mm Hg. Intravenous epoprostenol was started at
an initial dose of 2 ng/kg/min, increasing to a dose of 6 ng/kg/min.
During the intravenous epoprostenol therapy, inhaled NO was
discontinued. Systemic arterial pressure, CVP, LAP, CVP-LAP,
and PO2 remained unchanged (Figure 1), so inhaled NO was
successfully discontinued. The intravenous epoprostenol was dis-
continued 66 hours after the discontinuation of NO, without any
complications.
Discussion
Postoperative morbidity and mortality after Fontan-type operations
are mainly related to low cardiac output associated with high CVP
values as a result of elevated pulmonary vascular resistance. In the
early postoperative period, pulmonary vascular resistance is most
labile because of pulmonary endothelial dysfunction after cardio-
pulmonary bypass. Inhaled NO acts only locally in the adjacent
pulmonary smooth muscle cell, producing selective pulmonary
vasodilation. Although inhaled NO has this unusual property, the
use of this unstable gas has been limited under mechanical venti-
lation. The most serious complications of inhaled NO therapy are
rebound pulmonary hypertension2 and rebound oxygen desatura-
tion,3 along with coagulation inhibition and methemoglobinemia.
Pulmonary vasodilation achieved by the delivery of large doses of
exogenous NO could provoke secondary production or activation
of vasoconstrictors. With the short half-life NO, abrupt discontin-
uation could create a brief period of unobstructed vasoconstriction
until stimulation of endogenous vasodilators or a change in the
stimulus for vasoconstriction achieved a new balance of vasomotor
tone.
Exogenous epoprostenol administered intravenously is ac-
cepted as one of the pulmonary vasodilators of choice for patients
with severe pulmonary hypertension after heart operations.
Epoprostenol is naturally occurring endogenous vasodilator pro-
duced by the endothelium. Like all intravenous pulmonary vaso-
dilators, however, it is limited in its use by lack of specificity for
pulmonary vasculature, which may result in systemic hypotension.
Goldman and coworkers4 reported that an improvement in oxy-
genation was observed only with inhaled NO and not with epopro-
Figure 1. Time courses of PO2 (A) and CVP-LAP (B) in 2 patients. PGI2, Intravenous prostacyclin (epoprostenol).
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stenol in treating children with severe pulmonary hypertension
after cardiac surgery. Inhaled NO relieved the hypoxia-induced
vasoconstriction and improved ventilation-perfusion mismatch,
which intravenous epoprostenol aggravated. On the other hand,
Hermon and colleagues3 reported that intravenous epoprostenol
mitigates the inhaled NO rebound effect of oxygenation deterio-
ration in patients with pulmonary hypertension. Our preliminary
experience showed that combined therapy with inhaled NO and
intravenous epoprostenol was effective in preventing the critical
rebound after discontinuation of inhaled NO therapy. The intrave-
nous administration of epoprostenol was discontinued without any
rebound effects or complications.
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